The embattled AstraZeneca COVID-19 vaccine came under further pressure on Wednesday, as the European Union’s medicines regulator found a possible link between the shot and rare cases of blood clots, while the United Kingdom announced it would offer young people an alternative jab due to such risks.
The European Medicines Agency’s (EMA) widely anticipated verdict on Wednesday concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of the vaccine, but recommended that vaccinations continue in adults, reiterating its stance that the benefits of the shot outweigh any risks.
Al Jazeera’s Jonah Hull reports from London, UK.
- Subscribe to our channel: http://aje.io/AJSubscribe
- Follow us on Twitter: https://twitter.com/AJEnglish
- Find us on Facebook: https://www.facebook.com/aljazeera
- Check our website: https://www.aljazeera.com/
#AstraZeneca #Covid19Vaccine #EuropeanMedicinesAgency
The European Medicines Agency’s (EMA) widely anticipated verdict on Wednesday concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of the vaccine, but recommended that vaccinations continue in adults, reiterating its stance that the benefits of the shot outweigh any risks.
Al Jazeera’s Jonah Hull reports from London, UK.
- Subscribe to our channel: http://aje.io/AJSubscribe
- Follow us on Twitter: https://twitter.com/AJEnglish
- Find us on Facebook: https://www.facebook.com/aljazeera
- Check our website: https://www.aljazeera.com/
#AstraZeneca #Covid19Vaccine #EuropeanMedicinesAgency
- Category
- World
- Tags
- al jazeera, al jazeera english, aljazeera
Sign in or sign up to post comments.
Be the first to comment